| CAS登錄號(hào) | 中文名 | 英文名 | 分子結(jié)構(gòu)式 | 分子式 | 詳情 | 供應(yīng)商 |
| 126601-86-3 | Cleromyrin II (9CI); Dipyrrolo[1,2-a:1',2'-g][1,4,7,10,13,16]hexaazaCyclooctadecine,cyclic peptide deriv.; Cyclo(glycyl-L-prolyl-L-leucyl-L-prolylglycyl-L-tyrosyl) |  | C29H40N6O7 | 詳情 | 供應(yīng)商 | |
| 31556-84-0 | Monamycin I (8CI,9CI); 2H-Dipyridazino[1,6-d:1',6'-g]pyrrolo[1,2-m][1,4,7,10,13,16]oxapentaazaCyclooctadecine,cyclic peptide deriv.; D-Isoleucine, N-[1-[N-[[2-[[D-trans-5-chlorohexahydro-2-(L-erythro-2-hydroxy-3-methyl-1-oxopentyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-,p-lactone; N-[1-[N-[[2-[[D-trans-5-Chlorohexahydro-2-(L-erythro-2-hydroxy-3-methyl-1-oxopentyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-D-isoleucinep-lactone |  | C35H58ClN7O8 | 詳情 | 供應(yīng)商 | |
| 31556-81-7 | Monamycin G2 (8CI,9CI); 2H-Dipyridazino[1,6-d:1',6'-g]pyrrolo[1,2-m][1,4,7,10,13,16]oxapentaazaCyclooctadecine,cyclic peptide deriv.; D-Isoleucine, N-[1-[N-[[2-[[D-trans-5-chlorohexahydro-2-(L-2-hydroxy-3-methyl-1-oxobutyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-L-prolyl]-,p-lactone; N-[1-[N-[[2-[[D-trans-5-Chlorohexahydro-2-(L-2-hydroxy-3-methyl-1-oxobutyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-L-prolyl]-D-isoleucinep-lactone |  | C33H54ClN7O8 | 詳情 | 供應(yīng)商 | |
| 31556-77-1 | Monamycin B3 (8CI,9CI); 2H-Dipyridazino[1,6-d:1',6'-g]pyrrolo[1,2-m][1,4,7,10,13,16]oxapentaazaCyclooctadecine,cyclic peptide deriv.; D-Valine, N-[1-[N-[[2-[[D-hexahydro-2-(L-erythro-2-hydroxy-3-methyl-1-oxopentyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-L-prolyl]-,p-lactone; N-[1-[N-[[2-[[D-Hexahydro-2-(L-erythro-2-hydroxy-3-methyl-1-oxopentyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-L-prolyl]-D-valinep-lactone |  | C33H55N7O8 | 詳情 | 供應(yīng)商 | |
| 31594-06-6 | Monamycin H1 (8CI,9CI); 2H-Dipyridazino[1,6-d:1',6'-g]pyrrolo[1,2-m][1,4,7,10,13,16]oxapentaazaCyclooctadecine,cyclic peptide deriv.; D-Valine, N-[1-[N-[[2-[[D-trans-5-chlorohexahydro-2-(L-erythro-2-hydroxy-3-methyl-1-oxopentyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-,p-lactone; N-[1-[N-[[2-[[D-trans-5-Chlorohexahydro-2-(L-erythro-2-hydroxy-3-methyl-1-oxopentyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-D-valinep-lactone |  | C34H56ClN7O8 | 詳情 | 供應(yīng)商 | |
| 31556-79-3 | Monamycin D2 (8CI,9CI); 2H-Dipyridazino[1,6-d:1',6'-g]pyrrolo[1,2-m][1,4,7,10,13,16]oxapentaazaCyclooctadecine,cyclic peptide deriv.; D-Isoleucine, N-[1-[N-[[2-[[D-hexahydro-2-(L-2-hydroxy-3-methyl-1-oxobutyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-,p-lactone; N-[1-[N-[[2-[[D-Hexahydro-2-(L-2-hydroxy-3-methyl-1-oxobutyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-D-isoleucinep-lactone |  | C34H57N7O8 | 詳情 | 供應(yīng)商 | |
| 31556-82-8 | Monamycin G3 (8CI,9CI); 2H-Dipyridazino[1,6-d:1',6'-g]pyrrolo[1,2-m][1,4,7,10,13,16]oxapentaazaCyclooctadecine,cyclic peptide deriv.; D-Valine, N-[1-[N-[[2-[[D-trans-5-chlorohexahydro-2-(L-erythro-2-hydroxy-3-methyl-1-oxopentyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-L-prolyl]-,p-lactone; N-[1-[N-[[2-[[D-trans-5-Chlorohexahydro-2-(L-erythro-2-hydroxy-3-methyl-1-oxopentyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-L-prolyl]-D-valinep-lactone |  | C33H54ClN7O8 | 詳情 | 供應(yīng)商 | |
| 28045-02-5 | Monamycin D1 (8CI,9CI); 2H-Dipyridazino[1,6-d:1',6'-g]pyrrolo[1,2-m][1,4,7,10,13,16]oxapentaazaCyclooctadecine,cyclic peptide deriv.; D-Valine, N-[1-[N-[[2-[[D-hexahydro-2-(L-erythro-2-hydroxy-3-methyl-1-oxopentyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-,p-lactone; N-[1-[N-[[2-[[D-Hexahydro-2-(L-erythro-2-hydroxy-3-methyl-1-oxopentyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-D-valinep-lactone |  | C34H57N7O8 | 詳情 | 供應(yīng)商 | |
| 31556-83-9 | Monamycin H2 (8CI,9CI); 2H-Dipyridazino[1,6-d:1',6'-g]pyrrolo[1,2-m][1,4,7,10,13,16]oxapentaazaCyclooctadecine,cyclic peptide deriv.; D-Isoleucine, N-[1-[N-[[2-[[D-trans-5-chlorohexahydro-2-(L-2-hydroxy-3-methyl-1-oxobutyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-,p-lactone; N-[1-[N-[[2-[[D-trans-5-Chlorohexahydro-2-(L-2-hydroxy-3-methyl-1-oxobutyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-D-isoleucinep-lactone |  | C34H56ClN7O8 | 詳情 | 供應(yīng)商 | |
| 31556-76-0 | Monamycin B2 (8CI,9CI); 2H-Dipyridazino[1,6-d:1',6'-g]pyrrolo[1,2-m][1,4,7,10,13,16]oxapentaazaCyclooctadecine,cyclic peptide deriv.; D-Isoleucine, N-[1-[N-[[2-[[D-hexahydro-2-(L-2-hydroxy-3-methyl-1-oxobutyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-L-prolyl]-,p-lactone; N-[1-[N-[[2-[[D-Hexahydro-2-(L-2-hydroxy-3-methyl-1-oxobutyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-L-prolyl]-D-isoleucinep-lactone |  | C33H55N7O8 | 詳情 | 供應(yīng)商 | |
| 31556-75-9 | Monamycin B1 (8CI,9CI); 2H-Dipyridazino[1,6-d:1',6'-g]pyrrolo[1,2-m][1,4,7,10,13,16]oxapentaazaCyclooctadecine,cyclic peptide deriv.; D-Valine, N-[1-[N-[[2-[[D-hexahydro-2-(L-2-hydroxy-3-methyl-1-oxobutyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-,p-lactone; N-[1-[N-[[2-[[D-Hexahydro-2-(L-2-hydroxy-3-methyl-1-oxobutyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-D-valinep-lactone |  | C33H55N7O8 | 詳情 | 供應(yīng)商 | |
| 31594-05-5 | Monamycin F (8CI,9CI); 2H-Dipyridazino[1,6-d:1',6'-g]pyrrolo[1,2-m][1,4,7,10,13,16]oxapentaazaCyclooctadecine,cyclic peptide deriv.; D-Isoleucine, N-[1-[N-[[2-[[D-hexahydro-2-(L-erythro-2-hydroxy-3-methyl-1-oxopentyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-,p-lactone; N-[1-[N-[[2-[[D-Hexahydro-2-(L-erythro-2-hydroxy-3-methyl-1-oxopentyl)-3-pyridazinyl]carbonyl]-L-hexahydro-cis-5-hydroxy-3-pyridazinyl]carbonyl]-N-methyl-D-leucyl]-trans-4-methyl-L-prolyl]-D-isoleucinep-lactone |  | C35H59N7O8 | 詳情 | 供應(yīng)商 | |
| 40471-97-4 | 5,6,14,15-DIBENZO-4,7,13,16,21,24-HEXAOXA-1,10-DIAZABICYCLO[8.8.8]HEXACOSANE; 5,6,14,15-DIBENZO-4,7,13,16,21,24-HEXAOXA-1,10-DIAZABICYCLO[8.8.8]HEXACOSANE; KRYPTOFIX 222 BB; KRYPTOFIX(R) 222 BB; 6,7,9,10,17,18,20,21-octahydro-8,19-(ethanoxyethanoxyethano)-8H,19H-dibenzo[b,k][1,4,10,13,7,16]tetraoxadiazaCyclooctadecine; KRYPTOFIX 222 BB 99+%; 8,19-(Ethanoxyethanoxyethano)-8H,19H-dibenzob,k1,4,10,13,7,16tetraoxadiazaCyclooctadecine, 6,7,9,10,17,18,20,21-octahydro-; 5,6:14,15-Bis(2-butene-1,4-diylidene)-1,10-diaza-4,7,13,16,21,24-hexaoxabicyclo[8.8.8]hexacosane; 6,7,9,10,17,18,20,21-Octahydro-8,19-(ethanoxyethanoxyethano)-8H,19H-dibenzo[b,k][1,4,10,13,7,16]tetraoxadiazaCyclooctadecine |  | C26H44N2O6 | 詳情 | 供應(yīng)商 | |